Wholebody MRI In Lung Cancer StagiNg

Lung Cancer Clinical Trial

— WISLON  

Official title:

Initial Staging of Bronchopulmonary Neoplasia: Whole-body MRI Versus Pet Scanner

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02716051
• Other study ID #: I15037/WILSON
• Status: Completed
• Phase: N/A
• Start date: March 2016
• Est. completion date: June 2019

Study information

• Verified date: July 2019
• Source: University Hospital, Limoges
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Magnetic Resonnace Imaging (MRI) and Positron Emission Tomography (PET) can be both used in detection of nodes in patients with cell lung cancer (NSCLC).

However, the cardiorespiratory synchronization in the MRI, allowing acquisition of synchronous images with breathing and heart movements should increase the sensitivity of detection of pathologic mediastinal lymph nodes.

Given its high sensitivity, whole-body MRI with diffusion could possibly be at least as informative as PET, while being less expensive, not radiant.

The purpose of this study is to evaluate the performance of whole-body MRI with diffusion with cardiorespiratory synchronization, on the detection of mediastinal nodes (which are known to be less well detected by MRI) compared to PET.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: June 2019
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• At least 18 years,

• Neoplasia bronchopulmonary (SCLC and NSCLC) newly diagnosed,

• Patient potentially eligible for curative treatment, but no no treatment started,

• Patients for whom a PET scan and MRI are planned

Non Inclusion Criteria:

• claustrophobia,

• Implantable Medical Device

• not compatible pacemaker type or heart valve, metal splinters eye)

• Pregnant or lactating women,

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Intervention

Device:
• MRI
Whole body MRI with cardiac and pulmonary synchronization
• PET

Locations

Country	Name	City	State
France	CHU Limoges	Limoges

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Limoges

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Th consistency of the locations of mediastinal lesions	Node localization according to MRI and PET scan measurements on the same day	Day 1